Vinorelbine

Generic Name: Vinorelbine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₄₅H_₅₄N_₄O_₈

CAS Number: 71486-22-1

Unique Ingredient Identifier: Q6C979R91Y

Background: Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .

It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting .

A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug .

Indication: Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .

Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .

For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate .

For the treatment of recurrent or metastatic squamous cell head and neck cancer .

For the treatment of recurrent ovarian cancer .

For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy .

For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus .

Associated Conditions: Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma

Associated Therapies: -

Clinical Trials

Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

Phase 3

Completed

Conditions: Metastatic Triple Negative Breast Cancer

Interventions: Biological: pembrolizumab
Drug: capecitabine
Drug: eribulin
Drug: gemcitabine
Drug: vinorelbine

First Posted Date: 2015-09-21

Last Posted Date: 2021-12-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 622

Registration Number: NCT02555657

Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM

Phase 1

Completed

Conditions: Malignant Pleural Mesothelioma (MPM)
Non Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Vinorelbine

First Posted Date: 2015-09-21

Last Posted Date: 2022-11-17

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 30

Registration Number: NCT02555007

Locations: 🇫🇷
Assistance Publique des Hôpitaux de Marseille (CEPCM), Marseille, France

Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer

Phase 2

Conditions: Metastatic Breast Cancer

Interventions: Drug: Vinorelbine
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2015-09-09

Last Posted Date: 2015-09-09

Lead Sponsor: Shandong Cancer Hospital and Institute

Target Recruit Count: 200

Registration Number: NCT02544243

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

Phase 3

Conditions: HER2-positive Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Docetaxel
Drug: Pertuzumab
Drug: Paclitaxel
Drug: Nab-paclitaxel
Drug: Vinorelbine
Drug: Eribulin
Drug: Capecitabine
Drug: Gemcitabine

First Posted Date: 2015-08-04

Last Posted Date: 2020-01-07

Lead Sponsor: Japan Breast Cancer Research Group

Target Recruit Count: 370

Registration Number: NCT02514681

Locations: 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
🇯🇵
Kumamoto University Hospital, Kumamoto City, Kumamoto, Japan
🇯🇵
Aichi Cancer Center, Chikusa-ku, Aichi, Japan

Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC

Phase 4

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Endostatin
Drug: Vinorelbine
Drug: Cisplatin

First Posted Date: 2015-07-14

Last Posted Date: 2015-07-14

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT02497118

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

Phase 2

Conditions: Breast Neoplasms

Interventions: Drug: EndostarTM Injection
Drug: Gemcitabine
Drug: Navelbine
Drug: Platinum

First Posted Date: 2015-07-03

Last Posted Date: 2017-07-17

Lead Sponsor: Xinjiang Medical University

Target Recruit Count: 120

Registration Number: NCT02489409

Locations: 🇨🇳
Third Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Neuroendocrine Tumors
Small Cell Carcinoma
Ovarian Epithelial Cancer

Interventions: Drug: Cisplatin
Drug: RRx-001
Drug: Carboplatin
Drug: Etoposide
Drug: Paclitaxel
Drug: Doxil
Drug: Irinotecan
Drug: Nab-Paclitaxel
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Taxane
Drug: Pemetrexed

First Posted Date: 2015-07-03

Last Posted Date: 2022-10-03

Lead Sponsor: EpicentRx, Inc.

Target Recruit Count: 139

Registration Number: NCT02489903

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Baptist Health, Lexington, Kentucky, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States

and more 7 locations

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: Cisplatin
Drug: Vinorelbine
Drug: Docetaxel
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2015-07-01

Last Posted Date: 2024-08-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1280

Registration Number: NCT02486718

Locations: 🇪🇸
Hospital NisA 9 de Octubre, Valencia, Spain
🇨🇳
Zhejiang Cancer Hospital, Zhejiang, China
🇫🇷
Hôpital Universitaire Dupuytren, Limoges, France

and more 225 locations